^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF-A inhibitor

    Related drugs:
    12h
    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=558, Recruiting, BioNTech SE | N=144 --> 558
    Enrollment change • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • pumitamig (BNT327)
    16h
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=990, Recruiting, Bristol-Myers Squibb | N=346 --> 990
    Enrollment change • Trial initiation date
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • pumitamig (BNT327)
    17h
    Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Hospices Civils de Lyon | Recruiting --> Active, not recruiting
    Enrollment closed • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • ipatasertib (RG7440)
    18h
    4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=480, Active, not recruiting, 4D Molecular Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    18h
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=184, Recruiting, Bristol-Myers Squibb
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • pumitamig (BNT327)
    1d
    The Conjugation of Antibodies to Heat Shock Protein 70 Activates Immune Responses Against Tumor Cells. (PubMed, Immunotargets Ther)
    Recombinant HSP70, in conjugation with the monoclonal antibodies trastuzumab and bevacizumab, was employed for both in vivo and in vitro treatment of tumor cells. Histopathological analysis, along with the observed therapeutic efficacy, confirmed the safety of this approach. Overall, stimulating the immune system against cancer cells by targeting innate immune responses could enhance the effectiveness of targeted therapies.
    Journal
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab)
    1d
    A Case of Tegafur-Uracil-Induced Interstitial Lung Disease Presenting as Hypersensitivity Pneumonitis. (PubMed, Cureus)
    After receiving tegafur-uracil (UFT) plus leucovorin in combination with bevacizumab for rectal cancer, he developed exertional dyspnea. DI-ILD associated with UFT is rare, and to the best of our knowledge, no previous reports have described an HP pattern on imaging. We therefore report this case with a review of the relevant literature.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Avastin (bevacizumab) • tegafur/uracil
    1d
    ESM1 drives cancer angiogenesis and bevacizumab resistance via trioleate synthesis. (PubMed, Neoplasia)
    The ESM1-ANGPTL4-FASN-trioleate axis orchestrates metabolic reprogramming and endothelial activation, representing a promising therapeutic target. Future studies should explore combination therapies targeting this axis and overcoming bevacizumab resistance in HCC.
    Journal
    |
    FASN (Fatty acid synthase) • IL17A (Interleukin 17A) • CD99 (CD99 Molecule) • ANGPTL4 (Angiopoietin Like 4) • ESM1 (Endothelial Cell Specific Molecule 1)
    |
    Avastin (bevacizumab)
    1d
    A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P3, N=356, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    1d
    The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (clinicaltrials.gov)
    P2, N=30, Completed, Medical College of Wisconsin | Active, not recruiting --> Completed
    Trial completion
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Rubraca (rucaparib)